<unk>  (INN) is a protease inhibitor being studied as a treatment for hepatitis C.<unk>  is currently being marketed as Incivek. It has completed its phase III trials (ADVANCE;  A New Direction in HCV Care: A Study of Treatment-naïve Hepatitis C Patients with<unk>  in previously untreated patients with genotype 1, the most common strain in North American and Europe It is an orally bioavailable inhibitor of the nonstructural 3/4A (NS3/4A) HCV serine protease.   It was approved by the FDA on May 23rd, 2011 as a hepatitis C virus protease inhibitor, making it the second direct-acting antiviral HCV drug therapy to be approved behind boceprevir.<unk>  is most successful in patients who have not yet been previously treated for the condition.2
Currently, it is reported by the World Health Organization that 170-180 million people worldwide suffer from the hepatitis C virus (HCV ) and it is considered to be a serious global health crisis.    It is the most common blood born infection worldwide.5 Of this population, at least 130 million patients are estimated to be chronic HCV carriers who are at severe risk of developing liver cirrhosis and liver cancer.4, 6 The HCV RNA genome serves as a template for viral replication and as a viral messenger RNA for viral production. It is translated into a polyprotein that is cleaved by proteases, and then viral assembly occurs.4
The previously leading treatment therapy, a regimen of pegylated interferon and ribavirin, was only effective in about 38% - 46% of patients.2  It was administered for 24 weeks in patients with genotypes 2 or 3, or for 48 weeks in patients with genotype 1, the most common strain in Europe and North America.2 Fortunately, the recently FDA approved<unk>  is a significant and improved development in the successful treatment of HCV.<unk>  is a polymerase-inhibiting direct-acting antiviral (DAA) agent that is to be administered to the patients in combination with peginterferon and ribavirin.1 DAA drug agents work to attack the virus directly; they work by different mechanisms of action than previous treatments which indirectly fought the virus by trying to boost the immune system.4,  The introduction of this drug has broadened treatment options for patients suffering HCV considerably with the main goal of treatment being the achievement of a sustained virologic response (SVR), defined as an undetectable serum HCV RNA level 24 weeks after cessation of therapy.2 The achievement of SVR means that the virus has been eradicated and will further complications such as cirrhosis and hepatocellular carcinoma (HCC) are prevented.1,4
Serine protease inhibitors such as<unk>  used in the treatment of HCV for post-translational processing and the inhibition viral replication. It is most successful when given in combination with peginterferon and ribavirin at achieving sustained virologic responses in most patients who have genotype 1. However, when used as monotherapy, without the combination of the other standard drugs, the body quickly develops resistance.6
Telaprevir
Abacavir
Saquinavir
Fosamprenavir
Simeprevir
Enfuvirtide
Entecavir
Tipranavir